We have previously shown that twice weekly treatment with recombinant human (rh)VEGF-A165b reverses both pain and neuronal terminal loss during experimental diabetes, and sensitisation of sensory neuronal TRPA1-evoked responses (Hulse et al., 2015). The gene discussed is TRPA1; the disease is diabetes mellitus.